Please login to the form below

Not currently logged in
Email:
Password:

transplants

This page shows the latest transplants news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

Characterised by a build-up of fat that can lead to fibrosis, cirrhosis and in some patients the need for a liver transplant, NASH is viewed as an emerging health crisis -

Latest news

More from news
Approximately 9 fully matching, plus 198 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Distasteful but…. In addition to pay-for-performance, other possible funding strategies under consideration include mandatory price limits; re-insurance (currently used for expensive transplant operations); risk pooling; and lease-like

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Many cell therapies require additional, costly procedures for administration such as an allogeneic stem cell transplant as well as adjuvant therapies. ... Many transplant centres in England, and in other countries, are funded with a single, fixed payment

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics